Subscribe for email alerts
Donate to Science & Enterprise
|
By Alan, on December 26th, 2019%
Many parts of a new model for fighting antibiotic resistance are in development, and the pieces still need to be assembled, but the outline of a precision-medicine rather than mass-produced drug model is beginning to emerge. . . . → Read More: Commentary – New Models Needed for Antibiotic Resistance
By Alan, on March 20th, 2019%
The commissioner of the Food and Drug Administration warned that the sharp rise in teen electronic cigarette use is an epidemic threatening the public health. . . . → Read More: FDA Chief Calls Teen Vaping an “Epidemic”
By Alan, on February 10th, 2019%
Before we start celebrating the end of injections, we need to deal with a more basic problem facing people with diabetes, namely the rapidly rising cost of insulin. . . . → Read More: Insulin Delivered by Capsule, That’s the Good News
By Alan, on February 3rd, 2019%
Michael Lewis describes in a gripping narrative some of those critical life-protecting functions the federal government performs in his new book The Fifth Risk. . . . → Read More: Book Review – The Fifth Risk
By Alan, on September 12th, 2018%
A clinical trial with a design that allows for changes in its processes to meet the needs of individual patients says its results helped advance 7 new drugs for breast cancer into review by FDA. . . . → Read More: Personalized Breast Cancer Trial Advances 7 Drugs
By Alan, on May 12th, 2018%
Although he called it, “the most sweeping action in history to lower the price of prescription drugs for the American people,” the plan was anything but that. . . . → Read More: You Call That a Drug Pricing Policy?
By Alan, on December 1st, 2017% A panel convened by the National Academies calls for the federal government to use its buying power to negotiate better drug prices for consumers. . . . → Read More: Drug Price Report Calls for Govt Negotiation, More Generics
By Alan, on October 28th, 2017% Let’s be clear — the limited steps ordered by the president to reduce the numbers of people addicted to opioids don’t look anything like a response to an emergency. . . . → Read More: Here’s What a Real Opioid Emergency Looks Like
By Alan, on October 4th, 2017% Science & Enterprise is taking a break From 2 to 13 October. Until then, we will re-run some of our recent special reports. Our regular posts will return on 16 October.
(TBIT/Pixabay)
2 May 2016. At a press event in Washington, D.C. last week, Representative Lloyd Doggett of Texas, a champion of lower . . . → Read More: Flashback: Drug Pricing Reform Even Big Pharma Might Like
By Alan, on July 12th, 2017% A panel of research executives from American universities said the current hostility to immigration in the U.S. is causing fear among many researchers and could have a serious impact on science. . . . → Read More: Immigration Crackdown “a Disaster” for U.S. Science
|
Welcome to Science & Enterprise Science and Enterprise is an online news service begun in 2010, created for researchers and business people interested in taking scientific knowledge to the marketplace.
On the site’s posts published six days a week, you find research discoveries destined to become new products and services, as well as news about finance, intellectual property, regulations, and employment.
|
You must be logged in to post a comment.